Overview

To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

The primary objectives are to determine the relationship between blood levels of CDP6038 and suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV) infusion or subcutaneous (SC) injection to Rheumatoid Arthritis (RA) patients. The safety of CDP6038 will also be evaluated.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

UCB Pharma

Treatments:

Methotrexate